RecruitingMajor Depressive Disorder

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Eligible age

18–74 yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Sponsor: Definium Therapeutics US, Inc.

You may qualify if…

✓ 1. Diagnosis of MDD per DSM-5
✓ 2. Male or female aged 18 to 74
✓ 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration
✓ 4. MADRS Total Score ≥26
✓ 5. CGI-S Score ≥4

You may not qualify if…

✕ 1. Certain psychiatric disorders (other than major depressive disorder)
✕ 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
✕ 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine
✕ 4. Any clinically significant unstable illness